Universitätsklinikum Schleswig-Holstein (UKSH)

Juckreiz, Schlafstörungen, depressive Symptome, Fatigue und Einschränkungen der Arbeitsproduktivität bei Patienten mit moderater bis schwerer atopischer Dermatitis: Daten aus dem TREATgermany-Register (2023) Birkner T, Siegels D, Heinrich L, Haufe E, Abraham S, Heratizadeh A, Harder I, et al. Journal article S3-Leitlinie “Aktinische Keratose und Plattenepithelkarzinom der Haut“ – Update 2023, Teil 1: Therapie der aktinischen Keratose, Morbus Bowen, Cheilitis actinica, berufsbedingte Erkrankung und Versorgungsstrukturen (2023) Heppt M, Leiter U, Steeb T, Alter M, Amaral T, Bauer A, Bechara FG, et al. Journal article Preferences of German and Swiss melanoma patients for toxicities versus melanoma recurrence during adjuvant treatment (GERMELATOX-A-trial) (2023) Kähler KC, Hüning S, Nashan D, Meiss F, Rafei-Shamsabadi DA, Rissmann H, Colapietro C, et al. Journal article COMBI-r: A Prospective, Non-Interventional Study of Dabrafenib Plus Trametinib in Unselected Patients with Unresectable or Metastatic BRAF V600-Mutant Melanoma (2023) Berking C, Livingstone E, Debus D, Loquai C, Weichenthal M, Leiter U, Kiecker F, et al. Journal article Laboratory and free-living gait performance in adults with COPD and healthy controls (2023) Buekers J, Megaritis D, Koch S, Alcock L, Ammour N, Becker C, Bertuletti S, et al. Journal article Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG (2023) Haist M, Stege H, Rogall F, Tan Y, von Wasielewski I, Klespe KC, Meier F, et al. Journal article Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3- ITD mutations: results of the SAL MIDOKIT trial (2023) Ruhnke L, Röllig C, Herold S, Sauer T, Brandts CH, Steffen B, Schäfer-Eckart K, et al. Journal article Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial (2023) Williams TM, Schneeweiss A, Jackisch C, Shen C, Weber KE, Fasching P, Denkert C, et al. Journal article Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp (2023) Hassel JC, Berking C, Forschner A, Gebhardt C, Heinzerling L, Meier F, Ochsenreither S, et al. Journal article Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) study (2023) Lodde GC, Hassel J, Wulfken LM, Meier F, Mohr P, Kähler K, Hauschild A, et al. Journal article